GlaxoSmithKline Receive FDA Warning After Inspection

Avandia manufacturers, GlaxoSmithKline, recently receive U.S. Food and Drug Administration (FDA) warnings after the FDA uncovered information on the type 2 diabetes drug to have been withheld by the company.

Rosiglitazone maleate is the generic name of Avandia, which is taken orally to control insulin levels in the body. The New England Journal of Medicine released Avandia study results that linked the drug to an increased risk of heart disease, since that time, the drug's sales have decreased and it is no longer the best-selling diabetic drug, as news reports once stated.

The report, released in May 2007, found that patients were more likely to suffer from heart disease after taking Avandia for a period of time and individuals with a history of heart disease were likely to suffer a worse outcome, as the drug increased the ill-effects of heart disease among patients and resulted in death from cardiovascular-related causes. In fact, the study found a 43 percent increased risk of myocardial infarction, otherwise known as a heart attack. After the May 2007 reports of Avandia increasing the risk of heart disease, the drug has seen a decline in sales and both regulators in the U.S. market and European market have increased warnings on the drug.

GlaxoSmithKline did not adequately meet the deadline set by the FDA in their reporting of Avandia clinical trials. The FDA's regulations require that after-market results are given to FDA officials. The Avandia studies were over a six-year period ranging from 2001 to 2007. In November 2007 the FDA completed a routine inspection of the company and drug. Officials found that information from the trials was not adequately presented and information remained missing.

GlaxoSmithKline responded by stating that the information that was withheld from FDA officials had nothing to do with the potential safety risks of the drug and since the FDA inspection, the company has claimed that new training methods and programs have been implemented to avoid the loss of data reported to the FDA.

Avandia was approved for market in May 1999 and has been used as a potential drug to benefit Alzheimer's disease as well as to treat type 2 diabetes. Presently, approximately 3.5 million individuals taking Avandia, although, that number has likely decreased with the continuation of negative reports surrounding the drug. In addition to the risk of heart disease, Avandia has been associated with other serious side effects including an increased risk of osteoporosis and bone fractures among patients. Additionally, it was discovered that individuals taking Avandia have a slowed process of bone development, according to the Salk Institute for Biological Studies, which determined the disruption of osteoblasts and osteoclasts; however, clinical trials continue.

Other common side effects of the drug include headache, inflammation of sinuses, weight gain, back pain, swelling or fluid retention. Individuals who have taken Avandia and been victim to the serious side effects of the drug should speak with an experienced pharmaceutical attorney, as the potential for an Avandia lawsuit exists and may result in monetary compensation for the damage done to an individual's health.

LegalView.com, the number one resource for everything legal on the Web, has more information on Avandia at avandia.legalview.com, as well as other issues Americans are inflicted with, such as brain injury accidents, mesothelioma lawsuits or pharmaceutical recalls such as the Chantix risks, chantix.legalview.com/.

Please Rate this Article

5 out of 54 out of 53 out of 52 out of 51 out of 5 

Not yet Rated